Literature DB >> 32414804

COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.

Edoardo Conticini1, Elena Bargagli2, Marco Bardelli3, Giuseppe Domenico Rana2, Caterina Baldi3, Paolo Cameli2, Stefano Gentileschi3, David Bennett2, Paolo Falsetti3, Nicola Lanzarone2, Francesca Bellisai3, Cristiana Barreca3, Roberto D'Alessandro3, Luca Cantarini3, Bruno Frediani3.   

Abstract

Entities:  

Keywords:  antirheumatic agents; autoimmune diseases; sarcoidosis

Year:  2020        PMID： 32414804     DOI： 10.1136/annrheumdis-2020-217681

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  22 in total

1.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

2.  Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study.

Authors:  Ana Rita Cruz-Machado; Sofia C Barreira; Matilde Bandeira; Marc Veldhoen; Andreia Gomes; Marta Serrano; Catarina Duarte; Maria Rato; Bruno Miguel Fernandes; Salomé Garcia; Filipe Pinheiro; Miguel Bernardes; Nathalie Madeira; Cláudia Miguel; Rita Torres; Ana Bento Silva; Jorge Pestana; Diogo Almeida; Carolina Mazeda; Filipe Cunha Santos; Patrícia Pinto; Marlene Sousa; Hugo Parente; Graça Sequeira; Maria José Santos; João Eurico Fonseca; Vasco C Romão
Journal:  Front Med (Lausanne)       Date:  2022-06-13

Review 3.  COVID-19 and rheumatoid arthritis.

Authors:  Kristin M D'Silva; Zachary S Wallace
Journal:  Curr Opin Rheumatol       Date:  2021-05-01       Impact factor: 5.006

4.  Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic.

Authors:  Fatih Haslak; Mehmet Yildiz; Amra Adrovic; Sezgin Sahin; Oya Koker; Ayten Aliyeva; Kenan Barut; Ozgur Kasapcopur
Journal:  Rheumatol Int       Date:  2020-07-13       Impact factor: 2.631

Review 5.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2021-01-27       Impact factor: 20.999

6.  Potential of regulatory T-cell-based therapies in the management of severe COVID-19.

Authors:  Emmanuel Stephen-Victor; Mrinmoy Das; Anupama Karnam; Bruno Pitard; Jean-François Gautier; Jagadeesh Bayry
Journal:  Eur Respir J       Date:  2020-09-03       Impact factor: 16.671

7.  Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.

Authors:  Fernando Montero; Julia Martínez-Barrio; Belén Serrano-Benavente; Teresa González; Javier Rivera; Juan Molina Collada; Isabel Castrejón; Jose Álvaro-Gracia
Journal:  Rheumatol Int       Date:  2020-08-13       Impact factor: 2.631

8.  COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort.

Authors:  Greta Pellegrino; Davide Mohammad Reza Beigi; Carlotta Angelelli; Katia Stefanantoni; Marius Cadar; Silvia Mancuso; Fabrizio Conti; Valeria Riccieri
Journal:  Clin Rheumatol       Date:  2020-11-14       Impact factor: 2.980

9.  Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients.

Authors:  Elliot H Akama-Garren; Jonathan X Li
Journal:  J Med Virol       Date:  2021-06-02       Impact factor: 20.693

10.  Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.

Authors:  Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Hafize Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-02       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.